|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02877 SHINEWAY PHARM
Nominal 
8.260 +0.070 (+0.855%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 1,181,083 | -28.536% | 3,135,419 | 3,778,043 | 4,516,538 | 3,950,636 |
| Cost of Sales | (355,468) | -22.572% | (869,212) | (946,294) | (1,122,419) | (1,012,322) |
| Gross Profit | 825,615 | -30.830% | 2,266,207 | 2,831,749 | 3,394,119 | 2,938,314 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (20) | -- | (35,735) | (6,612) | (5,440) | (8,828) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 568,309 | -26.639% | 1,269,266 | 1,145,721 | 1,240,253 | 917,025 | |
| Taxation | (99,151) | -38.036% | (319,318) | (305,669) | (270,743) | (194,252) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 469,158 | -23.672% | 949,948 | 840,052 | 969,510 | 722,773 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 2,211 | -- | (210,675) | (170,589) | (92,470) | (91,801) |
| Depreciation & Amortisation | 70,698 | -4.378% | 70,884 | 68,735 | 60,233 | 58,686 |
| Directors' Emoluments | -- | -- | 13,486 | 14,122 | 42,317 | 11,849 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 62.000 | -23.457% | 126.000 | 111.000 | 128.000 | 96.000 |
| DPS (cts) | 123.000 | -- | 47.000 | 54.000 | 42.000 | 32.000 |
| Dividend Payout Ratio (%) | 198.387% | -- | 37.302% | 48.649% | 32.813% | 33.333% |
| Cash flow per share ($) | -- | -- | 1.552 | 1.275 | 1.235 | 1.469 |
| NBV per share ($) | 9.923 | -- | 9.748 | 9.029 | 8.506 | 7.718 |
| Remarks: | Real time quote last updated: 04/09/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 469,158 |
| %Change | -23.672% |
| EPS / (LPS) | RMB 0.620 |
| NBV Per Share (¥) | RMB 9.923 |